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Abstract
Background: In patients with chronic hepatitis C virus (HCV) genotype 2 or 3, 24 weeks’ treatment with pegylated
interferon alfa (PEG-IFN-alpha) and ribavirin induces a sustained virological response (SVR) in almost 80% of cases.
Evidence suggests that a similar response rate may be obtained with shorter treatment periods, especially in
patients with a rapid virological response (RVR). The aim of this study was to compare the efficacy of 12 or 24
weeks of treatment in patients with chronic HCV genotype 2 or 3 and to identify patients suitable for 12 weeks
treatment.
Methods: Two hundred and ten patients received PEG-IFN-alpha-2a (180 ug/week) and ribavirin (800-1200 mg/
day) for 4 weeks. Patients with a RVR (HCV RNA not detectable) were randomized (1:1) to either 12 (group A1) or
24 (group A2) weeks of combination therapy. Patients without a RVR continued with 24-weeks’ combination
therapy (group B). HCV RNA was monitored at weeks 4, 8, 12, and 24, and at week 24 post-treatment.
Results: At study end, end of treatment response (ETR) was observed in 62 (86%) patients of group A1 and in 55
(77%) patients of group A2 (p < 0.05) Relapse rate was 3% each in groups A1 and A2, and 6% in group B. Among
patients with a HCVRNA test 24 weeks after the end of treatment, SVR was observed in 60 (83%) of group A1
patients and in 53 (75%) of group A2 patients. Rapid virological response, low baseline HCV RNA levels, elevated
alanine aminotransferase levels and low fibrosis score, were the strongest covariates associated with SVR,
independent of HCV genotype. No baseline characteristic was associated with relapse.
Conclusion: In HCV patients with genotype 2 or 3, 12-week combination therapy is as efficacious as 24-week
therapy and several independent covariates were predictive of SVR.
Trial registration: Trial number ISRCTN29259563
Background
Pegylated interferon alpha (PEG-IFN-a) and ribavirin
administered in combinati o nf o rap e r i o do f2 4o r4 8
weeks ensure a sustained virological response (SVR) in
most patients with chronic hepatitis C virus (HCV)
infection and genotype 2 or 3 [1-3]. A shorter course of
therapy with PEG-IFN-a-2b and ribavirin has been
shown to be as effective as a 24-week course for patients
with HCV genotype 2 or 3, especially those with a rapid
virological response (RVR) [4,5]. Upon initiation of
interferon therapy, there is a rapid decline in viral load,
reflecting the efficiency of interferon-dependent inhibi-
tion of the production of the virus, its release, or both
[4]. This rapid decline is followed by a slower decrease
in viral load that is dependent on the rate of death of
infected cells and is estimated to vary from 1.7 days to
more than 70 days [6]. The rate of decline in the second
phase is eight times faster in patients with genotype 2
or 3 compared with patients with genotype 1 [7,8]. This
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or 3 infection may need shorter courses of therapy than
the regimens currently recommended [4]. Changes in
viremia levels over the first weeks of therapy correlate
with the likelihood of the eradication of HCV, and
undetectable viral levels at week 12 are predictive of a
response after 48 weeks of therapy [9,10]. Preliminary
clinical data have shown that in patients with HCV gen-
otype 2 or 3 in whom HCV RNA is not detectable after
4 weeks of therapy, 12 weeks of treatment with PEG-
IFN-a-2a or 2b and ribavirin in combination may be as
effective as the recommended course of 24 weeks
[4,11-13]. This is in agreement with the hypothesis
based on viral kinetics data [14]. We therefore con-
ducted a randomized clinical trial to assess whether a
12-week regimen of a combination of PEG-IFN-a-2a
and ribavirin was as efficacious as a 24-week regimen in
patients with HCV genotype 2 or 3.
Methods
Objective and hypothesis
The following hypothesis was tested: in patients with
HCV genotype 2 or 3 and with an RVR, 12 weeks of
treatment with PEG-IFN-a-2a at a dose of 180 μgs u b -
cutaneously once weekly and oral ribavirin, at a dosage
of 800-1200 mg/day is comparable to a 24 weeks treat-
ment. Futhermore, it was hypothesized that a 12 weeks
treatment had fewer side effects respect to 24 weeks
course.
Patient selection
Patients were eligible for inclusion if they were
HCVRNA positive, had HCV genotype 2 or 3, had ele-
v a t e da l a n i n ea m i n o t r a n s f e r a s e( > 4 0U I / L )a tl e a s t8
months prior to study entry and had an histologically
proven chronic HCV hepatitis. Patients were excluded if
they were known to have injected drugs or alcohol
abuse (>40 g ethanol/day) within the 6 months prior to
study entry; had poorly controlled psychiatric illness;
had decompensated cirrhosis; were positive for human
immunodeficiency antibody virus or positive for hepati-
tis B surface antigen. Additional criteria for exclusion
were: pregnancy, lactation, impaired renal function, and
other concurrent medical conditions of the liver differ-
ent from HCV infection.
Study design
Patients fulfilling the selection criteria received in an
open-label fashion PEG-IFN-a-2a at a dose of 180 μg
subcutaneously once weekly and oral ribavirin, at a
dosage of 800 mg/day (for those with a weight of < 65
kg), 1000 mg/day (for those with a weight between 65
and 85 kg) or 1200 mg/day (for those with a weight >
85 Kg). Patients with Rapid Virological response (RVR)
defined as HCVRNA <50 UI/ml after 4 weeks of treat-
ment, were randomly assigned in a 1:1 ratio to receive a
treatment either for 12 (Group A1) or 24 (Group A2)
weeks. Patients without RVR were treated for a standard
period of 24 weeks (Group B) (Figure 1).
Study endpoints
The primary efficacy endpoint was SVR which was
defined as undetectable plasma HCVRNA (<50 UI/ml)
24 weeks after the end of treatment. All the patients
who withdrew from the study and with HCV-RNA
detectable at 24 weeks after the end of the treatment,
were defined as non-responders. Patients experiencing
adverse events during the study had their dose of riba-
virin reduced to 800 mg/day. Hematological biochemical
testing in participants were performed, on an outpatient
basis, at weeks 4, 8, 12, 16 and 24 during treatment, and
24 weeks after the end of treatment. Dose reduction or
suspension of study drugs was considered if serious
adverse effects occurred. Adherence to treatment was
assessed using patient diaries.
Virology
HCV-RNA determination was performed with the
COBAS Amplicore HCV test (lower detection level 50
UI/ml). HCV genotyping was performed with the use of
Figure 1 CLEO study design. During the treatment phase, all
patients received PEG-IFN-a-2a 180 μg/week + ribavirin 800-1200
mg/day. PEG-IFN = pegylated interferon
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netics) All quantifications were performed at one central
laboratory. HCV-RNA analysis was performed at week
4, at the end of treatment (12 or 24 weeks) and 24
weeks after the end of treatment.
Liver Biopsy
Liver biopsies were obtained from all patients within 20
months prior to study entry. Only biopsy with a length
exceeding 1 cm and containing more than 6 portal
tracts were evaluated. All the biopsy were graded by two
indipendent observers and the evaluation was performed
according to the Ishak score [15].
Statistical analysis
The noninferiority margin was set at 20% between
Groups A1 and A2. To obtain 80% statistical power
with alpha level = 0.05, and Beta = 0.20, approximately
70 patients per treatment group were necessary. Initial
enrollment plans included 210 patients. Intention to
treat analysis was performed. All data were expressed as
t h em e d i a na n dr a n g ef o rd i s c r e t ev a r i a b l e sa n da s
counts and percentage for qualitative variables. Continu-
ous data were analysed using the Mann-Whitney test
and the Wilcoxon signed rank test for paired analyses.
Categorical data were analysed using the chi-square test
with the Yates’s correction and the Fisher’s exact test.
The relationship between pretreatment independent
covariates and the rate of SVR was examined by step-
wise logistic regression analysis with related odds ratio
and 95% confidence intervals (95% CI). For logistic
regression analysis pretreatment covariates of all patients
enrolled in the study were considered.
Ethics
The study was approved by a central ethic committee (S.
Camillo Hospital, Rome, Italy) and was conducted
according to the guidelines of the International Confer-
ence on Harmonization for Good Clinical Practice. All
patients gave their written informed consent prior to
treatment.
Results
Enrollment in the CLEO Centers started in July 2006,
and the trial ended in January 2008. Two hundred and
ten outpatients were consecutively enrolled. Baseline
characteristics of the patients enrolled for the study are
reported in Table 1.
RVR
One hundred and forty-three patients (68%); 79 with
genotype 2 and 64 with genotype 3 had a RVR to treat-
ment at week 4 (Group A). Of those, 72 were rando-
mized to receive combination treatment for 12 weeks
(Group A1) and 71 to receive treatment for 24 weeks
(Group A2). Sixty-seven patients (32%) did not achieve
a RVR at week 4 and continued with combination ther-
apy for 24 weeks (Group B). The characteristics of
patients with RVR are reported in Table 2.
SVR
According to intention to treat analysis, ETR was
observed in 62 patients (86%) of group A1, in 55
patients (77%) of group A2 and in 37 patients (55%) of
group B. During the follow-up period, relapse was
observed in 2 patients of Group A1 (one each with gen-
otype 2 and genotype 3), in 2 patients of Group A2
(both with genotype 3) and in 4 patients of Group B
(one with genotype 2 and three with genotype 3).
Patients who relapsed, after a wash-out period of 6
months, received treatment for a further 24 weeks and,
of these, 5 patients (2 of Group A1, 1 of Group A2, and
2 of Group B) subsequently showed a SVR. Two of
these patients had genotype 2 and 3 had genotype 3.
According to intention to treat analysis, SVR was
observed in 60 patients of Group A1 (83%; 32 with gen-
otype 2 and 28 with genotype 3), in 53 patients of
Group A2 (75%; 31 with genotype 2 and 22 with geno-
type 3), and in 33 patients of Group B (49%; 15 with
genotype 2 and 18 with genotype 3) (Table 3).
Factors associated with SVR
Stepwise logistic regression analysis showed that RVR
(odds ratio, 3.5; 95% CI, 2.2-8.3; P < 0.001), pretreat-
ment HCV RNA levels of ≤ 5l o g 10 UI/mL (odds ratio,
3.2; 95% CI, 1.2-7.2; P < 0.001), ALT levels ≥ 150 U.I./L
Table 1 Baseline characteristics of 210 patients enrolled
for the study
Characteristic
Male, n (%) 170 (81)
Age, years 43 (20-68)
Body mass index, kg/m
2 24 (21-32)
V iral Load
-<400.000 UI/ml 104(49)
->400.000 UI/ml 106(51)
Route of Trasmission
-Intravenous drug use 142(68)
-Transfusion 26(12)
- Unknown 42(20)
Alanine aminotransferase, IU/L 147 (96-255)
HCV genotype 2, n (%) 116 (55)
HCV genotype 3, n (%) 94 (45)
Cirrhosis (Ishak stage 5-6) n (%) 21 (10)
Bridging fibrosis (Ishak stage 3-4) n (%) 41 (19)
All values are expressed as median (range) unless otherwise specified.
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Page 3 of 6(odds ratio, 3.1; 95% CI, 1.4-6.8; P < 0.001), and fibrosis
score ≤ 3 (odds ratio, 3.2; 95% CI, 1.3-7.5; P < 0.001)
were the strongest covariates independently associated
with SVR (Table 4). None of the baseline characteristics,
including HCV genotype, were significantly associated
with relapse.
Safety profile
Five patients of Group A2 (7%) and 7 of Group B (10%)
withdrew from the study due to different adverse effects.
No patient of Group A1 withdrew from the study
because of adverse effects. (p < 0.05 compared with
Group B). Adverse events related to treatment in the 3
study groups are reported in the Table 5.
Discussion
Our study confirmed the hypothesis that in patients
with HCV genotype 2 or 3, a strategy of variable-dura-
tion treatment with PEG-IFN-a-2a and ribavirin
achieves rates of SVR similar to those achieved with
standard treatment, with a low rate of relapse. Accord-
ing to logistic regression analysis, a RVR is an indepen-
dent covariate that is predictive of a SVR, along with
pretreatment HCV-RNA levels, ALT values and fibrosis
scores. Moreover, in our study, treatment for 12 weeks
was associated with fewer adverse effects and less with-
drawals from therapy, compared with treatment for 24
weeks, without significant difference in the rate of
relapse.
I nt h eA C C E L E R A T Es t u d y[ 1 6 ] ,t h er a t eo fS V Ri n
patients treated with PEG-IFN-a-2a and ribavirin for 16
weeks was lower than that in patients treated for 24
weeks (62% vs 70%). But among patients with a RVR,
the rate of SVR was comparable to that observed in our
study (79% vs 85%) [16]. The fixed dose of ribavirin
(800 mg/day) administered during the ACCELERATE
study may account for the reduced rate of SVR observed
in patients treated for 16 weeks, since a weight-depen-
dent dosage of ribavirin may increase the rate of SVR in
patients treated with a short-term schedule. However,
our results are in agreement with those reported by von
Wagner et al.[17] from a randomized study comparing
16 weeks with 24 weeks of combination therapy with
PEG-IFN-a-2a plus a weight-dependent ribavirin dosage
in patients infected with HCV genotype 2 or 3. In this
study, combination therapy for 16 or 24 weeks achieved
rates of SVR among patients with a RVR at week 4 that
were similar to SVR rates reported in our study [17].
Our results are also in agreement with those reported
by Mangia et al. [4] and by Dalgard et al.[18], in which
Table 2 Patients characteristics according to achievement of rapid virological response.
Characteristic Group A (n = 143) Group B (n = 67) P value
Male, no. (%) 116 (81) 54 (80) NS
Age, years 42 (20-68) 45 (37-66) NS
Body mass index, kg/m
2 24 (22-32) 25 (21-30) NS
V iral Load
-<400.000 UI/ml 83(58) 22(33) < 0.01
->400.000 UI/ml 60(42) 45(67) < 0.01
Route of Trasmission
-Intravenous drug use 94(66) 48(72) NS
-Transfusion 17(12) 9 (13) NS
- Unknown 32(22) 10(15) NS
Alanine aminotransferase, IU/L 150(98-255) 145 (96-208) NS
HCV genotype 2, n (%) 79 (55) 37 (55) NS
HCV genotype 3, n (%) 64 (45) 30 (45) NS
Cirrhosis (Ishak stage 5-6) n(%) 13 (9) 8 (12) NS
Bridging fibrosis (Ishak stage 3-4) n(%) 26 (18) 15 (22) NS
All values are expressed as median (range) unless otherwise specified.
Table 3 Virological response observed in the study groups 24 weeks after the end of the treatment
Virological response Group A1 (n = 72) Group A2 (n = 71) Group B (n = 67)
Sustained virological response n.(%) 60 (83)* 53(75)† 33 (49)
Non sustained virological response n.(%) 12 (17) 18 (25) 34 (51)‡
*P < 0.001 compared with Group B
† P < 0.01 compared with Group B
‡ P < 0.001 compared with Group A1. P < 0.01 compared with Group A2.
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(adjusted for weight) was associated with a significant
rate of SVR, in patients with genotype 2 or 3 who had
achieved an RVR.
Although in our study the rate of response at week 4
was greater in patients with genotype 2 (55% vs 45%),
the rates of SVR were similar in patients with genotype
2 or 3 who had an RVR and who were treated for either
12 or 24 weeks. This finding is in agreement with that
reported by Mangia et al.[4] and by Neumann et al. in
the DITTO study [14] where the role of genotype
appears to be relatively small after early viral clearance.
However, among patients who did not achieve an RVR
and who were treated for 24 weeks, the rate of SVR was
higher, although not statistically significant, among
those with HCV genotype 2 than among those with gen-
otype 3 (60% vs 40%).
In our study we have observed a slight increase of
SVR in patients of Group A1 compared with Group A2,
however, without a difference statistically significant. A
higher incidence of cirrhotic patients in group A2 and
more frequent ribavirin dose modification could explain
this behavior. In the study of Lagging et al. [19] treat-
ment for 12 weeks in HCV infection with genotype 2 or
3 was inferior to 24 weeks of treatment. But 53% of all
patients in this study had bridging fibrosis or cirrhosis
compared with only 18% in the study of Mangia et al
[4], 23% in that of Dalgard et al.,24% in the ACCELER-
ATE trial and 29% in our study. Moreover, in the study
of Lagging et al., moderate or severe hepatic steatosis
was present in 26% of all the patients and this could
have contributed as cofactor in non response to antiviral
treatment and in a reduced rate of SVR.
Conclusions
In conclusion, our findings suggest that patients with
HCV infection with genotype 2 or 3 who have undetect-
able HCV-RNA levels after 4 weeks of treatment with
PEG-IFN-a-2a and ribavirin may achieve high virologi-
cal response rates with 12 weeks of therapy and do not
require 24 weeks of treatment, especially if they have
low HCV-RNA levels, high ALT levels, and a low fibro-
sis score at baseline. In fact, in this subset of patients,
short-term therapy may improve the clinical outcome of
HCV with fewer adverse effects related to long-term
therapy.
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